Modeling of dose–response–time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles

The most common approach to in vivo pharmacokinetic and pharmacodynamic modeling involves sequential analysis of the plasma concentration versus time and then response versus time data, such that the plasma kinetic model provides an independent function, driving the dynamics. However, response versus time data, even in the absence of measured drug concentrations, inherently contain useful information about the turnover characteristics of response (turnover rate, half‐life of response), the drug's biophase kinetics (F, half‐life) as well as the pharmacodynamic characteristics (potency, intrinsic activity). Previous analyses have assumed linear kinetics, linear dynamics, no time lag between kinetics and dynamics (single‐valued response), and time constant parameters. However, this report demonstrates that the drug effect can be indirect (antinociception, cortisol/adrenocorticotropin (ACTH), body temperature), display nonlinear kinetics, display feedback mechanisms (nonstationarity, cortisol/ACTH) and exhibit hysteresis with the drug levels in the biophase (antinociception, body temperature). It is also demonstrated that crucial determinants of the success of modeling dose–response–time data are the dose selection, multiple dosing, and to some extent different input rates and routes. This report exemplifies the possibility of assigning kinetic forcing functions in pharmacodynamic modeling in both preclinical and clinical studies for the purpose of characterizing (discrimination between turnover and drug‐specific parameters) response data and optimizing subsequent clinical protocols, and for identification of inter‐individual differences. Copyright © 2000 John Wiley & Sons, Ltd.

[1]  D. Jackson,et al.  A pharmacological validation of radiotelemetry in conscious, freely moving rats. , 1998, Journal of pharmacological and toxicological methods.

[2]  G. Graham,et al.  Pharmacokinetic Analysis of the Effect of Vecuronium in Surgical Patients: Pharmacokinetic and Pharmacodynamic Modeling without Plasma Concentrations , 1998, Anesthesiology.

[3]  W. Jusko,et al.  An improved pharmacodynamic model for formation of methemoglobin by antimalarial drugs. , 1995, Drug metabolism and disposition: the biological fate of chemicals.

[4]  N. Modi,et al.  A system approach to pharmacodynamics. Input-effect control system analysis of central nervous system effect of alfentanil. , 1993, Journal of pharmaceutical sciences.

[5]  W J Jusko,et al.  Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. , 1971, Journal of pharmaceutical sciences.

[6]  V F Smolen,et al.  Quantitative determination of drug bioavailability and biokinetic behavior from pharmacological data for ophthalmic and oral administrations of a mydriatic drug. , 1971, Journal of pharmaceutical sciences.

[7]  G. Levy,et al.  Kinetics of pharmacologic effects in man: The anticoagulant action of warfarin , 1969, Clinical pharmacology and therapeutics.

[8]  G Levy,et al.  Kinetics of pharmacologic effects , 1966, Clinical pharmacology and therapeutics.

[9]  G. Levy,et al.  RELATIONSHIP BETWEEN ELIMINATION RATE OF DRUGS AND RATE OF DECLINE OF THEIR PHARMACOLOGIC EFFECTS. , 1964, Journal of pharmaceutical sciences.

[10]  C. Li,et al.  The dynamics of adrenocortical secretion. , 1968, The American journal of physiology.